BACKGROUND: A consensus definition of acute kidney injury (AKI)-the risk, injury, failure, loss, and end-stage kidney disease (RIFLE) classification-predicts mortality in general hospital and ICU populations. We aimed to assess its value on admission in patients with community-acquired pneumonia (CAP). METHODS: A prospective observational study with CAP was carried out. We classified each patient according to his or her maximum RIFLE class using admission creatinine (risk, ≥ 1.5 × baseline creatinine; injury, ≥ 2 × baseline; failure, ≥ 3 × baseline; no-AKI, < 1.5 × baseline). Outcomes were 30-day mortality, requirement for mechanical ventilation and inotropic support (MV/IS), and requirement for renal replacement therapy (RRT). RESULTS: A total of 1,241 patients were included (no-AKI, 1,018; risk, 130; injury, 63; failure, 30). On multivariate analysis, factors predicting development of AKI include severity of pneumonia (adjusted odds ratio [AOR], 1.74; 95% CI, 1.46-2.08; P < .0001), elevated C-reactive protein (AOR, 1.04; 95% CI, 1.03-1.06; P < .0001), and prior use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II-receptor blockers (AIIBs) (AOR, 1.77; 95% CI, 1.19-2.58; P = .005). Adjusting for severity of pneumonia, RIFLE criteria independently predicted 30-day mortality (AOR, 1.48; 95% CI, 1.15-1.91; P = .002), requirement for MV/IS (AOR, 2.22; 95% CI, 1.74-2.83; P < .0001), and RRT (AOR, 3.20; 95% CI, 2.01-5.11; P < .0001). Prior use of ACEIs or AIIBs was not associated with adverse outcome in either the entire cohort or patients without AKI. CONCLUSION: The RIFLE classification is a simple tool to assess and classify AKI on admission and independently predicts 30-day mortality and the need for MV/IS and RRT in patients with CAP.
BACKGROUND: A consensus definition of acute kidney injury (AKI)-the risk, injury, failure, loss, and end-stage kidney disease (RIFLE) classification-predicts mortality in general hospital and ICU populations. We aimed to assess its value on admission in patients with community-acquired pneumonia (CAP). METHODS: A prospective observational study with CAP was carried out. We classified each patient according to his or her maximum RIFLE class using admission creatinine (risk, ≥ 1.5 × baseline creatinine; injury, ≥ 2 × baseline; failure, ≥ 3 × baseline; no-AKI, < 1.5 × baseline). Outcomes were 30-day mortality, requirement for mechanical ventilation and inotropic support (MV/IS), and requirement for renal replacement therapy (RRT). RESULTS: A total of 1,241 patients were included (no-AKI, 1,018; risk, 130; injury, 63; failure, 30). On multivariate analysis, factors predicting development of AKI include severity of pneumonia (adjusted odds ratio [AOR], 1.74; 95% CI, 1.46-2.08; P < .0001), elevated C-reactive protein (AOR, 1.04; 95% CI, 1.03-1.06; P < .0001), and prior use of angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin-II-receptor blockers (AIIBs) (AOR, 1.77; 95% CI, 1.19-2.58; P = .005). Adjusting for severity of pneumonia, RIFLE criteria independently predicted 30-day mortality (AOR, 1.48; 95% CI, 1.15-1.91; P = .002), requirement for MV/IS (AOR, 2.22; 95% CI, 1.74-2.83; P < .0001), and RRT (AOR, 3.20; 95% CI, 2.01-5.11; P < .0001). Prior use of ACEIs or AIIBs was not associated with adverse outcome in either the entire cohort or patients without AKI. CONCLUSION: The RIFLE classification is a simple tool to assess and classify AKI on admission and independently predicts 30-day mortality and the need for MV/IS and RRT in patients with CAP.
Authors: Isaac E Hall; Steven G Coca; Mark A Perazella; Umo U Eko; Randy L Luciano; Patricia R Peter; Won K Han; Chirag R Parikh Journal: Clin J Am Soc Nephrol Date: 2011-10-27 Impact factor: 8.237
Authors: Christina Bradshaw; Yuanchao Zheng; Samuel A Silver; Glenn M Chertow; Jin Long; Shuchi Anand Journal: J Gen Intern Med Date: 2018-06-18 Impact factor: 5.128
Authors: Carlos Franco Palacios; Mira T Keddis; Dingxin Qin; Ladan Zand; Guangxi Li; Xiangling Wang; Rodrigo Cartin-Ceba; Robert P Hartman; Qi Qian Journal: Int J Nephrol Date: 2011-07-25
Authors: Matthias Diebold; Tobias Zimmermann; Michael Dickenmann; Stefan Schaub; Stefano Bassetti; Sarah Tschudin-Sutter; Roland Bingisser; Corin Heim; Martin Siegemund; Stefan Osswald; Gabriela M Kuster; Katharina M Rentsch; Tobias Breidthardt; Raphael Twerenbold Journal: J Clin Med Date: 2021-05-25 Impact factor: 4.241
Authors: Tyler Pitre; Angela Hong Tian Dong; Aaron Jones; Jessica Kapralik; Sonya Cui; Jasmine Mah; Wryan Helmeczi; Johnny Su; Vivek Patel; Zaka Zia; Michael Mallender; Xinxin Tang; Cooper Webb; Nivedh Patro; Mats Junek; MyLinh Duong; Terence Ho; Marla K Beauchamp; Andrew P Costa; Rebecca Kruisselbrink; Jennifer L Y Tsang; Michael Walsh Journal: Can J Kidney Health Dis Date: 2021-07-11
Authors: Hamid Aslami; Wilco P Pulskens; Maria T Kuipers; Aafkeline P Bos; André B P van Kuilenburg; Ronald J A Wanders; Jeroen Roelofsen; Joris J T H Roelofs; Raphaela P Kerindongo; Charlotte J P Beurskens; Marcus J Schultz; Wim Kulik; Nina C Weber; Nicole P Juffermans Journal: PLoS One Date: 2013-05-23 Impact factor: 3.240